This comparison contains one of the genuine puzzles in metabolic pharmacology. Both drugs act at the GIP receptor — and they do opposite things to it. Tirzepatide activates it. MariTide blocks it. Both produce substantial weight loss.
They also differ in a way patients would notice immediately. Tirzepatide is a weekly injection. MariTide, built as a peptide-antibody conjugate, is being studied at monthly or less frequent dosing — roughly twelve injections a year instead of fifty-two.
At a glance
| Maridebart Cafraglutide | Tirzepatide | |
|---|---|---|
| Drug class | Peptide-antibody conjugate: GLP-1 agonist + GIP receptor antagonist | Small peptide: GIP + GLP-1 receptor agonist |
| Action at GIP receptor | Blocks it | Activates it |
| Dosing frequency | Monthly or less frequent (investigational) | Once weekly |
| Weight loss | Up to ~20% at about one year (Phase 2) | ~20–22% (SURMOUNT Phase 3 program) |
| Development stage | Phase 3 MARITIME programme ongoing | Approved; multiple indications |
| FDA status | Not approved | Approved for type 2 diabetes, weight management & obstructive sleep apnea |
| Main side effects | Nausea and vomiting, notably after early doses | Nausea, diarrhea, constipation |
| Availability | Clinical trials only | Prescription, widely available |
The bottom line
Bottom line: Tirzepatide is approved, extensively studied, and available now. MariTide is investigational, with Phase 2 weight loss in a broadly similar range and one clear potential advantage: monthly dosing. That convenience cuts both ways — a drug that stays in the body for weeks cannot be withdrawn quickly if it is poorly tolerated, and early trials saw meaningful nausea after initial doses. The mechanistic contradiction at the GIP receptor remains unresolved, and the fact that both approaches work suggests the field does not yet fully understand GIP's role in body weight.
Frequently asked questions
How is MariTide different from Zepbound?
Two ways. MariTide blocks the GIP receptor while activating GLP-1; tirzepatide (Zepbound) activates both. And MariTide is designed for monthly or less frequent dosing thanks to its antibody backbone, versus weekly for tirzepatide.
How can blocking and activating GIP both cause weight loss?
This is an open question. Possible explanations include GIP antagonism countering fat storage in adipose tissue, GIP agonism enhancing GLP-1's central effects, or sustained agonism ultimately desensitizing the receptor so that both approaches converge on a similar state.
Is monthly dosing better?
For adherence, probably — fewer injections is a real advantage in a therapy taken indefinitely. For safety management it is a trade-off, because a long-acting drug cannot be cleared quickly if side effects occur. Phase 3 will show how that balance plays out.
When will MariTide be available?
It is not approved and has no announced availability date. The Phase 3 MARITIME programme spans obesity, type 2 diabetes, cardiovascular outcomes, heart failure, and sleep apnea, and those trials must report before any regulatory submission.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. Peer-reviewed study
- Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024. Peer-reviewed study
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. Peer-reviewed study
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. Peer-reviewed study
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. Peer-reviewed study
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. Peer-reviewed study
- Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. Peer-reviewed study
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. Peer-reviewed study